Reviewed by The Peptide Dispatch Editorial Team · Last reviewed July 6, 2026
Hexarelin (HEX) is a growth hormone peptide, at the clinical trials stage in the published literature. The most potent synthetic GHRP available, providing the strongest GH release but with faster desensitization than other GHRPs.
The most potent synthetic GHRP available, providing the strongest GH release but with faster desensitization than other GHRPs.
| Research Status | Clinical trials |
|---|---|
| Half-Life | 20-30 minutes |
| Administration | Subcutaneous injection |
| Doses Reported in Published Studies | 100-200 mcg |
Highly potent ghrelin receptor agonist with strongest GH release among GHRPs. Causes rapid receptor desensitization.
The most potent synthetic GHRP available, providing the strongest GH release but with faster desensitization than other GHRPs.
Highly potent ghrelin receptor agonist with strongest GH release among GHRPs. Causes rapid receptor desensitization.
Hexarelin is at the following stage in the published literature: Clinical trials. All information is for research and educational purposes only.
Reported half-life: 20-30 minutes.
Reported administration route in the literature: Subcutaneous injection. This is not a recommendation for human use.
Educational content, not medical advice. Effects described are drawn from cited research in study subjects.